View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 9, 2017updated 13 Jul 2022 10:08am

Boehringer and Anthem begin trial to study treatment impact on COPD exacerbations

Boehringer Ingelheim has initiated a pragmatic clinical trial (AIRWISE) in partnership with Anthem and its outcomes research subsidiary HealthCore to investigate the impact of commonly prescribed medicines on exacerbations of chronic obstructive pulmonary disease (COPD).

Boehringer Ingelheim has initiated a pragmatic clinical trial (AIRWISE) in partnership with Anthem and its outcomes research subsidiary HealthCore to investigate the impact of commonly prescribed medicines on exacerbations of chronic obstructive pulmonary disease (COPD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An exacerbation is defined as sudden worsening of COPD symptoms such as increased breathlessness, cough, mucus production and extreme fatigue, leading to hospitalisation or death.

The primary focus of the randomised, open-label trial is to obtain better insights into the role of long-acting muscarinic antagonists (LAMA), long-acting ß-agonists (LABA) and inhaled corticosteroids (ICS) in decreasing the risk of exacerbations.

During the trial, the effectiveness of Stiolto Respimat Inhalation Spray will be compared with a commercially available LAMA, LABA and ICS combination in a real-life setting in 3,200 adults with COPD.

Stiolto Respimat is a fixed combination of tiotropium bromide (LAMA) and olodaterol (LABA).

“Due to the significant impact of exacerbations on the health of people with COPD, it is critical that their occurrence is reduced with the safest and most effective treatment plans.”

The trial will enrol patients who have been determined by a healthcare provider that they are not controlled with their current therapy of LAMA, LABA or ICS / LABA.

Boehringer Ingelheim Pharmaceuticals Primary Care Clinical Development and Medical Affairs vice-president Thomas Seck said: “Due to the significant impact of exacerbations on the health of people with COPD, it is critical that their occurrence is reduced with the safest and most effective treatment plans.

“Our partnership with Anthem and HealthCore is an important initiative to help healthcare providers understand how two treatment approaches work in the real world to reduce the occurrence of exacerbations.”

With results expected to be available in 2020, the AIRWISE trial will assess the time to first moderate or severe COPD exacerbation as its primary endpoint.

Additionally, the trial will compare an annual rate of moderate or severe COPD exacerbations, along with all-cause and COPD-related healthcare resource utilisation such as inpatient admissions, outpatient encounters, emergency room visits and office visits.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena